Moderna (MRNA) Cash from Investing Activities (2018 - 2026)

Moderna has reported Cash from Investing Activities for 9 years, with the latest figure at $329.0 million in Q2 2026.

• Cash from Investing Activities for Q2 2026 came in at $329.0 million, down 41.67% year-over-year; the trailing twelve-month figure through Jun 2026 was $905.0 million (down 38.69% YoY), and the FY2025 annual result was $1.9 billion, changed 0.15% from the prior year.
• Cash from Investing Activities improved to $329.0 million in Q2 2026, from -$76.0 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $2.0 billion in Q1 2023 and troughed at -$3.9 billion in Q1 2022.
• A 5-year average of $176.6 million and a median of $446.5 million in 2025 frame the typical range for Cash from Investing Activities.
• The widest annual swing landed in 2022, when Cash from Investing Activities tumbled 2078.33%; it then soared 518.64% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at -$1.0 billion in 2022, then soared by 48.66% to -$538.0 million in 2023, then declined by 0.19% to -$539.0 million in 2024, then jumped by 91.09% to -$48.0 million in 2025, then jumped by 785.42% to $329.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $329.0 million in Q2 2026, -$76.0 million in Q1 2026, and -$48.0 million in Q4 2025.